Corticobasal Degeneration (CBD) is a rare 4R tauopathy characterized by asymmetric parkinsonism, apraxia, cortical sensory loss, and alien limb phenomena. Currently, no disease-modifying therapies are approved for CBD, and treatment is multimodal: symptomatic pharmacotherapy, evidence-based neuroprotective supplementation, multidisciplinary rehabilitation, and palliative care integration[1]. CBD and Corticobasal Syndrome (CBS) are distinct concepts — CBD is the neuropathological diagnosis while CBS is the clinical phenotype, which can be caused by CBD, PSP, Alzheimer's disease, or other pathologies[2].
The CBS/PSP Treatment Rankings page ranks 55 interventions by evidence rubric. The CBS/PSP Daily Action Plan provides implementable protocols. The CBS/PSP Rehabilitation Guide details non-pharmacological approaches.
Levodopa response in CBD is characteristically poor compared to Parkinson's Disease, but a therapeutic trial is still recommended in all patients because the PSP-P and CBS-PD overlap phenotypes may show partial response[3].
| Medication | Mechanism | Dosing | Notes |
|---|---|---|---|
| Levodopa/carbidopa | Dopamine precursor | Titrate to 1000 mg/day | Declare non-response after 3-6 month trial at adequate dose[3:1] |
| Amantadine | NMDA antagonist + DA release | 100-200 mg BID | May reduce rigidity; monitor confusion in elderly[4] |
| Pramipexole | D2/D3 agonist | 0.375-1.5 mg/day | Impulse control disorder risk |
Botulinum toxin is first-line for several CBD-specific symptoms[5]:
Myoclonus — often cortical and stimulus-sensitive in CBD:
Rigidity and Akinesia:
The alien limb phenomenon — involuntary, purposeful-appearing movements of one limb — has no proven pharmacological treatment[6]. Management includes:
| Symptom | First-Line | Second-Line | Notes |
|---|---|---|---|
| Depression | SSRIs (sertraline 50-200 mg) | Mirtazapine, venlafaxine | Avoid tricyclics (cognitive burden)[7] |
| Apathy | Methylphenidate 5-20 mg/day | Modafinil 100-200 mg | Differentiate from depression |
| Pseudobulbar affect | Dextromethorphan/quinidine | SSRIs | FDA-approved combination |
| Irritability/aggression | Low-dose quetiapine 25-100 mg | Citalopram | Minimize antipsychotic dose |
| Anxiety | SSRIs, buspirone | Short-term benzodiazepines | Fall risk warning |
Cognitive impairment in CBD primarily affects executive function, with language deficits (non-fluent progressive aphasia) common[8]:
Dysphagia develops in most CBD patients and increases aspiration risk[9]:
CBD shares pathological mechanisms with PSP (4R tau, neuroinflammation, mitochondrial dysfunction), and neuroprotective strategies ranked for CBS/PSP apply to CBD. See the CBS/PSP Treatment Rankings for the full 55-intervention ranking[10].
Mediterranean/MIND Diet (64/80): Highest-ranked intervention with multi-target anti-inflammatory nutrition. The CBS/PSP Daily Action Plan provides texture-modified protocols for patients with dysphagia[11].
Structured Exercise (62/80): 150+ min/week aerobic, 2x/week resistance, daily balance exercises. See CBS/PSP Rehabilitation Guide for CBD-adapted protocols[12].
Rasagiline (60/80): MAO-B inhibitor; propargylamine moiety activates anti-apoptotic pathways independently of dopamine preservation[13].
Rapamycin (57/80): mTORC1 inhibitor restoring autophagy-mediated tau clearance; intermittent 5-6 mg/week dosing under investigation[14].
Low-Dose Lithium (55/80): GSK-3β inhibitor reducing tau phosphorylation at disease-relevant epitopes; 150-300 mg/day[15].
Alpha-Lipoic Acid (56/80): Mitochondrial antioxidant; R-enantiomer 600 mg/day.
TUDCA/UDCA (56/80): ER stress chemical chaperones; AMX0035 class evidence.
| Intervention | Score | Key Mechanism |
|---|---|---|
| Senolytics (D+Q) | 54/80 | Clear senescent glia, reduce SASP |
| NAD+ Precursors | 53/80 | Mitochondrial NAD+ repletion |
| Melatonin | 53/80 | Chronobiotic + tau kinase inhibition |
| Spermidine | 55/80 | Autophagy induction via EP300 inhibition |
| CoQ10 | 48/80 | Complex I electron carrier |
| Omega-3 DHA/EPA | 48/80 | SPM biosynthesis |
Physical therapy addresses the asymmetric motor features specific to CBD[12:1]:
Deep Brain Stimulation: Generally not effective in CBD due to diffuse cortical pathology. May be considered in rare cases with predominant parkinsonism and minimal cortical features[17].
Transcranial Magnetic Stimulation (rTMS): Investigational for cortical hyperexcitability; may provide transient motor benefit.
| Agent | Target | Phase | Status |
|---|---|---|---|
| Semorinemab | N-terminal tau | Phase 2 | Completed |
| Tilavonemab (ABBV-8E12) | Aggregated tau | Phase 2 | Completed — no efficacy[18] |
| Bepranemab (UCB0107) | Mid-domain tau | Phase 1/2 | Ongoing |
| BIIB080 (IONIS-MAPTRx) | MAPT mRNA (ASO) | Phase 1/2 | 50-60% CSF tau reduction[19] |
Optimal CBD management requires coordinated multidisciplinary care[21]:
| Team Member | Role | Frequency |
|---|---|---|
| Movement disorder neurologist | Diagnosis, pharmacotherapy, clinical trials | Every 3-6 months |
| Physical therapist | Gait, balance, contracture prevention | Weekly → biweekly |
| Occupational therapist | ADL adaptation, one-handed techniques, safety | Monthly → as needed |
| Speech-language pathologist | Aphasia therapy, swallowing, AAC | Weekly → monthly |
| Neuropsychologist | Cognitive assessment, behavioral strategies | Every 6-12 months |
| Social worker | Care coordination, caregiver support | As needed |
| Palliative care | Symptom management, advance directives | From diagnosis onward |
Given the predictable progressive course of CBD (median survival 6-8 years)[22]:
CBD presents with distinct clinical phenotypes that may guide treatment selection[2:1]:
The classic presentation with asymmetric rigidity, apraxia, cortical sensory loss, and alien limb phenomena represents approximately 40-50% of CBD cases. Treatment follows the standard approach outlined above, with emphasis on:
Some patients present with features of both CBS and PSP, including vertical gaze palsy and early falls. These patients may show better levodopa response and should receive a full levodopa trial[3:2].
Patients presenting with predominant visuospatial disorientation and behavioral changes require different management:
Language-predominant CBD requires speech-language pathology as the primary intervention:
Given the complex multi-system involvement in CBD, combination approaches may offer advantages[10:1]:
| Primary Treatment | Rationale | Adjunct Therapy |
|---|---|---|
| Levodopa + amantadine | Multiple dopaminergic mechanisms | Physical therapy |
| Clonazepam + levetiracetam | Different myoclonus mechanisms | Physical therapy |
| Cholinesterase + behavioral therapy | Cognition + environment | Speech therapy |
| Botulinum toxin + baclofen | Focal + generalized dystonia | PT/OT |
Sleep disturbances are common in CBD and worsen cognitive and motor symptoms[16:1]:
Chronic pain is underrecognized in CBD:
CBD places significant burden on caregivers[21:1]:
Treatment of CBD requires a comprehensive, multidisciplinary approach targeting the diverse motor, cognitive, and behavioral symptoms of this progressive tauopathy. While no disease-modifying therapies are currently available, the combination of evidence-based symptomatic treatments, neuroprotective strategies ranked by the CBS/PSP Treatment Rankings, and multidisciplinary rehabilitation can significantly optimize quality of life and functional outcomes. Patients should be enrolled in clinical trials when available, and advance care planning should begin early in the disease course.
Sleep disturbances are common in CBD and significantly impact quality of life[16:2]:
Sleep hygiene optimization:
Pharmacological interventions:
Treat underlying conditions:
Chronic pain is underrecognized but significantly impacts quality of life:
First-line:
Second-line:
Non-pharmacological:
Malnutrition and weight loss are common in CBD due to multiple factors[9:1]:
Baseline evaluation:
Dietary modifications:
Feeding support:
Falls:
Aspiration pneumonia:
Seizures:
Acute confusion:
Patients with CBD should be encouraged to participate in clinical trials[18:1][19:2]:
Active and Recent Trials:
CBD places substantial burden on caregivers[21:2]:
Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013. ↩︎
Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy. Neurology. 1996. ↩︎ ↩︎
Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy. Mov Disord. 2014. ↩︎ ↩︎ ↩︎
Lamb R, Rohrer JD, Lees AJ, Revesz T. Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options. Curr Treat Options Neurol. 2016. ↩︎
Scelzo E, Lozano AM, Bhatt M. Botulinum toxin in PSP blepharospasm and limb dystonia. J Neurol. 2003. ↩︎
Kertesz A, Martinez-Lage P, Davidson W, Munoz DG. The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology. 1994. ↩︎
Sturkenboom IH, Graff MJ, Hendriks JC, et al. Efficacy of occupational therapy for patients with Parkinson disease. Neurology. 2014. ↩︎
Kouri N, Murray ME, Hassan A, et al. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain. 2011. ↩︎
Müller J, Wenning GK, Verny M, et al. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol. 2001. ↩︎ ↩︎
Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy and atypical parkinsonism. Mov Disord. 2004. ↩︎ ↩︎
Morris MC, Tangney CC, Wang Y, et al. MIND diet slows cognitive decline with aging. Alzheimers Dement. 2015. ↩︎
Suteeratanapun J, et al. The role of rehabilitation in patients with progressive supranuclear palsy. Ann Indian Acad Neurol. 2018. ↩︎ ↩︎
Weinreb O, Mandel S, Youdim MBH, Amit T. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radic Biol Med. 2013. ↩︎
Cummings J, Lee G, Ritter A, Zhong K. Alzheimer's disease drug development pipeline. Alzheimers Dement. 2021. ↩︎
Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A. 2005. ↩︎
Kluin KJ, Foster NL, Berent S, Gilman S. Dysarthria and dysphagia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2001. ↩︎ ↩︎ ↩︎
Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol. 2012. ↩︎
Höglinger GU, Litvan I, Mendonca N, et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy. Lancet Neurol. 2021. ↩︎ ↩︎
Mummery CJ, Borber A, Murber M, et al. Tau-targeting antisense oligonucleotide BIIB080 in frontotemporal dementia. Nat Med. 2023. ↩︎ ↩︎ ↩︎
Wilcock GK, Gauthier S, Frisoni GB, et al. Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate) monotherapy. J Alzheimers Dis. 2018. ↩︎
Golbe LI. Progressive supranuclear palsy. Semin Neurol. 2014. ↩︎ ↩︎ ↩︎
Nath U, Ben-Shlomo Y, Thomson RG, et al. The prevalence of progressive supranuclear palsy in the UK. Brain. 2001. ↩︎